前列腺癌患者外周血中CD4^+CD25^(high)调节性T细胞及调节因子TGF-β1和COX-2的表达  

Expressions of CD4^+ CD25^(high) regulatory T cells,TGF-β1 and COX-2 in the peripheral blood of prostate cancer patients

作　　者：夏桃林[1,2] 刘涛 吴振权[2] 张海滨[2] 杨明[2] 刘绍远[2] 何灼彬 李辽源[3] 

机构地区：[1]东莞市大朗医院泌尿外科,广东东莞523770 [2]佛山市第一人民医院泌尿外科,广东佛山528000 [3]中山大学附属第三医院泌尿外科,广东广州510630

出　　处：《中华男科学杂志》2011年第10期888-893,共6页National Journal of Andrology

摘　　要：目的:通过检测前列腺癌患者以及健康志愿者外周血中CD4+CD25high调节性T细胞、TGF-β1及COX-2的表达,初步探讨CD4+CD25high调节性T细胞在前列腺癌发病机制中的作用及其与TGF-β1和COX-2的相关性。方法:应用流式细胞术检测30例前列腺癌患者治疗前后(其中前列腺癌局限组11例,非局限组19例)及20例健康志愿者外周血单个核细胞(PBMC)中CD4+CD25high调节性T细胞占CD4+T细胞的比例;应用酶联免疫吸附试验(ELISA)检测其外周血清中TGF-β1和COX-2的表达。对前列腺癌患者上述指标进行术前术后对比分析,另对CD4+CD25high调节性T细胞与TGF-β1及COX-2的相关性进行分析;并探讨上述指标在前列腺癌患者局限组和非局限组间是否存在差异性。结果:流式细胞术检测显示,前列腺癌患者治疗前PBMC中CD4+CD25high调节性T细胞占CD4+T细胞的比例为(18.32±7.49)%,高于健康志愿者对照组(7.77±1.86)%(P<0.05)。前列腺癌患者治疗后其比值为(17.34±5.87)%,较治疗前稍减低,但两者相比无显著差异(P>0.05)。ELISA检测外周血清中TGF-β1和COX-2显示,前列腺癌组分别为(215.97±55.16)ng/ml和(6.88±5.14)ng/ml,对照组分别为(149.75±47.11)ng/ml和(5.65±2.69)ng/ml;前列腺癌患者外周血清中TGF-β1的表达水平高于健康志愿者对照组(P<0.05),COX-2的表达水平与对照组无显著差异(P>0.05)。通过多重线性回归分析表明,前列腺癌患者PBMC中CD4+CD25high调节性T细胞的表达与血清中TGF-β1和COX-2的表达无显著相关。前列腺癌局限组和非局限组外周血中CD4+CD25high调节性T细胞、TGF-β1及COX-2的表达均无显著性差异(P>0.05)。结论:前列腺癌患者PBMC中CD4+CD25high调节性T细胞可能参与前列腺癌的发生,其增殖机制与血清中TGF-β1和COX-2的表达无关,可能与肿瘤本身及肿瘤局部微环境相关。Objective： To investigate the expressions of CD4＋ CD25high regulatory T cells,TGF-β1 and COX-2 in the periphe-ral blood of prostate cancer（PCa） patients,and analyze the role of CD4＋ CD25high regulatory T cells in the pathogenesis of PCa and their relationship with TGF-β1 and COX-2.Methods： We used flow cytometry to calculate the percentage of CD4＋CD25high regulatory T cells in the CD4＋ T cells in the peripheral blood mononuclear cells（PBMC） from 30 PCa patients（11 localized and 19 non-loca-lized cases） and 20 healthy volunteer controls,determined the expressions of TGF-β1 and COX-2 in the serum by ELISA,and analyzed their correlation with the CD4＋CD25high regulatory T cells in the PCa patients as well as the differences between the localized and non-localized cases.Results： CD4＋CD25high regulatory T cells accounted for（18.32±7.49） % in the CD4＋ T cells in PBMCs from the PCa patients,significantly higher than（7.77±1.86） % from the controls（P 0.05）,but with no statistically significant difference between pre-and post-treatment in the PCa patients（P 0.05）.The expressions of TGF-β1 and COX-2 in the peripheral blood were（215.97±55.16） ng/ml and（6.88±5.14） ng/ml in the PCa patients,in comparison with（149.75±47.11） ng/ml（P 0.05） and（6.88±5.14） ng/ml（P 0.05） in the controls.Multiple linear regression analysis showed no significant correlation between the expression of CD4＋CD25high regulatory T cells in PBMCs and those of TGF-β1 and COX-2 in the peripheral blood of the PCa patients.There were no significant differences between the localized and non-localized PCa groups in the expressions of CD4＋CD25high regulatory T cells,TGF-β1 and COX-2（P 0.05）.Conclusion： CD4＋CD25high regulatory T cells in in PBMCs are involved in the pathogenesis of PCa.The proliferation of CD4＋CD25high regulatory T cells is not significantly correlated to the expressions of TGF-β1 and COX-2 in the peripheral blood,but maybe to the tumor itself and the l

关 键 词：前列腺癌 CD4+CD25high调节性T细胞 转化生长因子Β1 环氧合酶-2 

分 类 号：R737.25[医药卫生—肿瘤]